Nothing Special   »   [go: up one dir, main page]

AR056217A1 - Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demencia - Google Patents

Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demencia

Info

Publication number
AR056217A1
AR056217A1 ARP060104956A ARP060104956A AR056217A1 AR 056217 A1 AR056217 A1 AR 056217A1 AR P060104956 A ARP060104956 A AR P060104956A AR P060104956 A ARP060104956 A AR P060104956A AR 056217 A1 AR056217 A1 AR 056217A1
Authority
AR
Argentina
Prior art keywords
heterocycloalkyl
alkyl
cycloalkyl
heteroaryl
aryl
Prior art date
Application number
ARP060104956A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38049090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056217(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Astex Therapeutics Ltd filed Critical Astrazeneca Ab
Publication of AR056217A1 publication Critical patent/AR056217A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable, tautomero o precursor hidrolizable in vivo de los mismos, en los cuales, G es O, NR7 o CR8R9; R1 es H, alquilo C1-6, haloalquilo C1-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con 1, 2, 3, 4 o 5 R14; R2 es Q o -L-Q; o R1 y R2, junto con el átomo de carbono al cual están unidos, forman un grupo cicloalquilo de 3-14 miembros o un grupo heterocicloalquilo de 3-14 miembros, cada uno de los cuales está sustituido con Cy2 y está optativamente sustituido con 1, 2, 3, 4 o 5 A4; R3, R4, R5 y R6 son, independientemente, H, CN, NO2, ORa, SRa, OC(O)Ra, OC(O)ORb, OC(O)NRcRd, C(O)Ra, C(O)ORb, C(O)NRcRd, NRcRd, NRcC(O)Ra, NRcC(O)ORb, NRcS(O)2Rb, S(O)Ra, S(O)NRcRd, S(O)2Ra, S(O)2NRcRd, alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con 1, 2 o 3 R14; R7 es H, C(O)Ra, C(O)ORb, C(O)NRcRd, S(O)Ra, S(O)2Ra, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde cada uno del alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido 1, 2, 3, 4 o 5 R14; R8 y R9 son, independientemente, H, CN, NO2, ORa, SRa, OC(O)Ra, OC(O)ORb, C(O)ORb, OC(O)NRcRd, NRcRd, NRcC(O)Ra, NRcC(O)ORb, NRcS(O)2Rb, S(O)Ra, S(O)NRcRd, S(O)2Ra, S(O)2NRcRd, alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2- 10, arilo, . cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con 1, 2 o 3 R14; o R8 y R9, junto con el átomo de carbono al cual están unidos, forman un grupo cicloalquilo de 3-14 miembros o un grupo heterocicloalquilo de 3-14 miembros, cada uno de los cuales está sustituido con 1, 2 o 3 R14; cada uno de R12 y R13 es, independientemente, H, halo, alquilo C1-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rd', NRc'C(O)ORa', NRc'S(O)2Rb', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', o S(O)2NRc'Rd'; R14 es halo, alquilo C1-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rd', NRc'C(O)ORa', NRc'S(O)2Rb', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', o S(O)2NRc'Rd'; Q es arilo, cicloalquilo, heteroarilo o heterocicloalquilo, cada uno de los cuales está optativamente sustituido con 1, 2, 3, 4 o 5 Cy1 o A1; L es alquenilenilo C2-10, alquinilenilo C2-10, (CR12R13)q, (CR12R13)q1O(CR12R13)q2, (CR12R13)q1S(CR12R13)q2, (CR12R13)q1SO2(CR12R13)q2, (CR12R13)q1SO(CR12R13)q2, (CR12R13)q1CO(CR12R13)q2, (CR12R13)q1NRe(CR12R13)q2, o (CR12R13)q1CONRe(CR12R13)q2; Cy1 es arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, cada uno de los cuales está optativamente sustituido con 1, 2, 3, 4 o 5 A2; Cy2 es arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, cada uno de los cuales está optativamente sustituido con 1, 2, 3, 4 o 5 A3; A1 es halo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rb, S(O)Rb, S(O)NRcRd, S(O)2Rb, o S(O)2NRcRd, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilalquilo, cicloalquilalquilo, heteroarilalquilo o heterocicloalquilalquilo, donde cada uno de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilalquilo, cicloalquilalquilo, heteroarilalquilo o heterocicloalquilalquilo está optativamente sustituido con 1, 2, 3, 4 o 5 halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rb', S(O)Rb, S(O)NRcRd, S(O)2Rb, o S(O)2NRcRd; cada uno de A2, A3, y A4 es, independientemente, halo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rb, S(O)Rb, S(O)NRcRd, S(O)2Rb, o S(O)2NRcRd, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, arilo, cicloalquilo, heteroarilo o heterocicloalquilo, donde cada uno de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, arilo, cicloalquilo, heteroarilo o heterocicloalquilo está optativamente sustituido con 1, 2, 3, 4 o 5 halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rb, S(O)Rb, S(O)NRcRd, S(O)2Rb, o S(O)2NRcRd; cada uno de Ra y Ra' es, independientemente, H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquillquilo o heterocicloalquilalquilo, donde el alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo, cada uno de Rb y Rb' es, independientemente, H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo, cada uno de Rc y Rd es, independientemente, H, alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo, o Rc y Rd junto con el átomo de N al cual están unidos, forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; cada uno de Rc' y Rd' es, independientemente, H, alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo, o bien Rc' y Rd' junto con el átomo de N al cual están unidos, forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; Re es H, alquilo C1-4, haloalquilo C1-4, alquenilo C2-4, alquinilo C2-4, o CO-(alquilo C1-4); q es 1, 2, 3, 4, 5 o 6; q1 es 0, 1, 2 o 3; y q2 es 0, 1, 2 o 3; con las siguientes salvedades: a) cuando G es NH o CH2; R2 es -L-Q; L es -CH2, -CH=CH-, o -CsC-; y R1 es H o metilo, luego Q no ha de ser fenilo no sustituido y b) cuando G es NR7 o CR8R9; R7 es H, metilo, o fenilo optativamente sustituido con halo; cada uno de R8 y R9 es independientemente, H o metilo, R2 es Q; y R1 es H o metilo, luego Q es arilo, cicloalquilo, heteroarilo, o heterocicloalquilo, cada uno de los cuales está optativamente sustituido con por lo menos un Cy3 y está optativamente sustituido con 1, 2 o 3 A4.
ARP060104956A 2005-11-15 2006-11-13 Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demencia AR056217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73732705P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
AR056217A1 true AR056217A1 (es) 2007-09-26

Family

ID=38049090

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104956A AR056217A1 (es) 2005-11-15 2006-11-13 Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demencia

Country Status (15)

Country Link
US (1) US20080293709A1 (es)
EP (1) EP1957462A4 (es)
JP (1) JP2009520685A (es)
KR (1) KR20080070744A (es)
CN (1) CN101360714A (es)
AR (1) AR056217A1 (es)
AU (1) AU2006316256A1 (es)
BR (1) BRPI0618607A2 (es)
CA (1) CA2629831A1 (es)
IL (1) IL191057A0 (es)
NO (1) NO20082481L (es)
TW (1) TW200804290A (es)
UY (1) UY29919A1 (es)
WO (1) WO2007058583A2 (es)
ZA (1) ZA200803859B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
BRPI0612545A2 (pt) 2005-06-14 2010-11-23 Schering Corp compostos inibidores de protease, composições farmacêuticas e uso dos mesmos
JP5281794B2 (ja) 2005-10-25 2013-09-04 塩野義製薬株式会社 アミノジヒドロチアジン誘導体
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
KR20100059919A (ko) 2007-09-24 2010-06-04 코멘티스, 인코포레이티드 치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물
US8217064B2 (en) * 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2305672B1 (en) 2008-06-13 2019-03-27 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
EP2349308A4 (en) 2008-10-10 2012-09-12 Purdue Research Foundation COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2376083A4 (en) 2008-11-20 2012-06-20 Purdue Research Foundation CHINAZOLIN INHIBITORS OF BACE 1 AND METHOD OF USE
US8859590B2 (en) 2008-12-05 2014-10-14 Purdue Research Foundation Inhibitors of BACE1 and methods for treating Alzheimer's disease
WO2011014462A1 (en) 2009-07-27 2011-02-03 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
KR20120104570A (ko) 2009-12-11 2012-09-21 시오노기세야쿠 가부시키가이샤 옥사진 유도체
JPWO2011077726A1 (ja) 2009-12-24 2013-05-02 塩野義製薬株式会社 ４−アミノ−１，３−チアジンまたはオキサジン誘導体
EP2580200B1 (en) 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
WO2012003392A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EA021723B1 (ru) 2010-09-22 2015-08-31 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 4,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-6-ИЛАМИНА, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (ВАСЕ)
JP5766198B2 (ja) * 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CA2816285A1 (en) * 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
MX347912B (es) 2010-12-22 2017-05-17 Janssen Pharmaceutica Nv Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8ilaminautiles como inhibidores de beta-secretasa (bace).
CA2824360C (en) 2011-03-01 2020-01-14 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
ES2534973T3 (es) 2011-03-09 2015-04-30 Janssen Pharmaceutica N.V. Derivados de 3,4-dihidro-pirrolo[1,2-a]pirazin-1-ilamina útiles como inhibidores de beta-secretasa (BACE)
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
JPWO2012147763A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
BR112014004181A2 (pt) 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
CA2912156C (en) 2013-06-12 2021-07-20 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
AU2014280124B2 (en) 2013-06-12 2018-11-01 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE)
EA028775B1 (ru) 2013-06-12 2017-12-29 Янссен Фармацевтика Нв Производные 4-амино-6-фенил-6,7-дигидро[1,2,3]триазоло[1,5-a]пиразина в качестве ингибиторов бета-секретазы (bace)
ES2768823T3 (es) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
EP0858451A1 (en) * 1995-10-17 1998-08-19 Astra Pharmaceuticals Limited Pharmaceutically active quinazoline compounds
KR20000005388A (ko) * 1996-04-13 2000-01-25 니콜라스 피터 비가르트 (니크 비가르트), 콜린 레드롭 아미노이소퀴놀린 및 아미노티에노피리딘 유도체 및 소염제로서의 그의 용도
US20030199526A1 (en) * 2001-12-07 2003-10-23 Deborah Choquette Pyrimidine-based compounds useful as GSK-3 inhibitors
PE20070078A1 (es) * 2005-06-14 2007-03-08 Schering Corp Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa

Also Published As

Publication number Publication date
NO20082481L (no) 2008-07-24
JP2009520685A (ja) 2009-05-28
WO2007058583A3 (en) 2007-07-05
KR20080070744A (ko) 2008-07-30
CA2629831A1 (en) 2007-05-24
AU2006316256A1 (en) 2007-05-24
UY29919A1 (es) 2007-06-29
WO2007058583A2 (en) 2007-05-24
IL191057A0 (en) 2008-12-29
ZA200803859B (en) 2009-02-25
EP1957462A4 (en) 2010-09-15
US20080293709A1 (en) 2008-11-27
CN101360714A (zh) 2009-02-04
TW200804290A (en) 2008-01-16
BRPI0618607A2 (pt) 2011-09-06
EP1957462A2 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
AR056217A1 (es) Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demencia
RU2009115963A (ru) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
JP2009520685A5 (es)
AR073530A1 (es) Inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos. inserto oftalmico
RU2430923C2 (ru) Тиазолилдигидрохиназолины
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
RU2016108987A (ru) Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
RU2009128591A (ru) Лиганды для визуализации иннервации сердца
RU2006122209A (ru) Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
RU2007139453A (ru) Гетеробициклические ингибиторы вируса гепатита с (hcv)
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
IL298983B1 (en) Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
ES2561507T3 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
HRP20130918T1 (hr) Derivati 4-aminopirimidina kao receptori antagonista histamina h4
AR045955A1 (es) Compuestos benzoimidazolicos
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
NO20081056L (no) Nye, heterosykliske NF-kB-inhibitorer
RU2012116526A (ru) Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
RU2014122335A (ru) ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGluR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal